Impact of a pharmacist adherence intervention on medication beliefs and drug-related problems in coronary patients - a process evaluation of the MIMeRiC trial.

BMC Health Serv ResSep 15, 2026 (epub)
Clinical ResearchCardiologyOpen access

Malin Johansson Östbring, Ahmed Al Musawi, Tommy Eriksson et al.

✦ AI-curated · Sources linked

In 30 seconds

The MIMeRiC randomized controlled trial assessed a pharmacist-led intervention in coronary patients, focusing on medication adherence and beliefs. The intervention group showed improved adherence to cholesterol-lowering medications and aspirin, with 52.8% shifting to a more accepting attitude towards medications compared to 31.0% in the control group (p = 0.051).

Key findings

  • Pharmacists identified 500 drug-related problems (DRPs) in 144 patients, managing 245 independently.
  • 194 out of 218 resolved or improved DRPs were documented.
  • The mean concern score on the Beliefs about Medicines Questionnaire decreased more in the intervention group.
  • 52.8% of intervention patients shifted to an accepting attitude towards medications compared to 31.0% in controls.

Why it matters

Improving medication adherence is crucial for managing coronary heart disease. This study highlights the role of pharmacists in addressing drug-related problems and enhancing patients' beliefs about their medications, which can lead to better health outcomes.

Source

PubMed · PMID 42760559Free full text on PubMed Central

Published in BMC Health Serv Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.